secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001140361-25-012944
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics announces FDA alignment supporting GTx-104 NDA submission; submission expected Q2 2025
--------------------------------------------------------------------------------

- Primary endpoint met: 19% reduction in clinically significant hypotension (28% GTx-104 vs 35% oral nimodipine).
- 54% of GTx-104 patients had relative dose intensity ≥95% vs 8% on oral nimodipine.
- 29% more patients had favorable functional outcomes at 90 days with GTx-104.
- 8 deaths on GTx-104 vs 4 on oral; none determined drug-related.
- NDA submission for GTx-104 anticipated in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125012944/0001140361-25-012944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125012944/ef20047157_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-012944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer